Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats

Inflammation Research

Volumn 61, Issue 6, 2012, Pages 551-562

  Haruta, Kazuhiko ^a   Mori, Shigeyuki ^a   Tamura, Naoto ^b   Sasaki, Asako ^a   Nagamine, Masakazu ^a   Yaguchi, Shin Ichi ^a   Kamachi, Fumitaka ^a   Enami, Jumpei ^a   Kobayashi, Shigeto ^c   Yamori, Takao ^d   Takasaki, Yoshinari ^b  

^a ZENYAKU KOGYO CO LTD   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Juntendo University Hospital   (Japan)

^d CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Adjuvant induced arthritis; IFN ; IL 17; PGE 2; Phosphatidylinositol 3 kinase

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; PROSTAGLANDIN E2; PROTEIN KINASE B;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBROBLAST; HISTOPATHOLOGY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MOUSE; NONHUMAN; OSTEOCLAST; PROTEIN PHOSPHORYLATION; RAT; SYNOVIOCYTE; T LYMPHOCYTE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CYTOKINES; DINOPROSTONE; FEMALE; FREUND'S ADJUVANT; LYMPH NODES; LYMPHOCYTES; MALE; MICE; MICE, INBRED DBA; MYCOBACTERIUM; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED LEW; SPLEEN; TRIAZINES;

EID: 84865120058     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0444-8     Document Type: Article

References (46)

1. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Lohr KN. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148:124-34. (Pubitemid 351651555)
2. Koyasu S. The role of PI3K in immune cells. Nat Immunol. 2003;4:313-9.
3. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3:317-30. (Pubitemid 37328684)
4. Kong D, Yamori T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem. 2009;16:2839-54.
5. Okkenhug K, Bilancio A, Emery JL, Vanhaesebroeck B. Phosphoinositide 3-kinase in T cell activation and survival. Biochem Soc Trans. 2004;32:332-5. (Pubitemid 38582121)
6. Rommel C, Camps M, Ji H. PI3Kd and PI3Kc: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol. 2007;7:191-201.
7. Fruman DA. Towards an understanding of isoform specificity in phosphoinositide 3-kinase signaling in lymphocytes. Biochem Soc Trans. 2004;32:315-9. (Pubitemid 38582117)
8. Soond DR, Bjørgo E, Moltu K, Dale VQ, Patton DT, Torgersen KM, Galleway F, Twomey B, Clark J, Gaston JS, Taskén K, Bunyard P, Okkenhaug K. PI3K p110d regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood. 2010;115:2203-13.
9. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S. Activation of synovial fibroblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res. 2000;2:59-64. (Pubitemid 32223701)
10. Zhang HG, Wang Y, Xie JF, Liang X, Liu D, Yang P, Hsu HC, Ray RB, Mountz JD. Regulation of tumor necrosis factor amediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis Rheum. 2001;44:1555-67. (Pubitemid 32642218)
11. Ludikhuize J, de Launay D, Groot D, Smeets TJ, Vinkenoog M, Sanders ME, Tas SW, Tak PP, Reedquist KA. Inhibition of forkhead box class O family member transcription factors in rheumatoid synovial tissue. Arthritis Rheum. 2007;56:2180-91. (Pubitemid 47173565)
12. Miyashita T, Kawakami A, Tamai M, Izumi Y, Mingguo H, Tanaka F, Abiru S, Nakashima K, Iwanaga N, Arateke K, Kamachi M, Arima K, Ida H, Migita K, Origuchi T, Tagashira S, Nishikaku F, Eguchi K. Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochem Biophys Res Commun. 2003;312:397-404. (Pubitemid 37445186)
13. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, Baharav E. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther. 2006;8:R33.
14. Wang CR, Shiau AL, Chen SY, Lin LL, Tai MH, Shieh GS, Lin PP, Yo YT, Lee CH, Kuo SM, Liu MF, Jou IM, Yang CY, Shen PC, Lee HL, Wu CL. Amelioration of collagen-induced arthritis in rats by adenovirus-mediated PTEN gene transfer. Arthritis Rheum. 2008;58:1650-6.
15. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95-105.
16. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996;15: 5256-67. (Pubitemid 26336209)
17. Schultz RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G. In vitro and in vivo antitumor activity of the phosphatidylinositol 3-kinase inhibitor wortmannin. Anticancer Res. 1995;15:1135-9.
18. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res. 2000;6: 880-6.
19. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C. Blockade of PI3Kc suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005;11:936-43. (Pubitemid 41294438)
20. Stangenberg L, Ellson C, Cortez-Retamozo V, Ortiz-Lopez A, Yuan H, Blois J, Smith RA, Yaffe MB, Weissleder R, Benoist C, Mathis D, Josephson L, Mahmood U. Abrogation of antibodyinduced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function. Arthritis Rheum. 2009;60:2314-24.
21. Newbould BB. Role of lymph nodes in adjuvant-induced arthritis in rats. Ann Rheum Dis. 1964;23:392-6.
22. Jacobson PB, Morgan SJ, Wilcox DM, Nguyen P, Ratajczak CA, Carlson RP, Harris RR, Nuss M. A new spin on an old model: in vivo evaluation of disease progression by magnetic resonance imaging with respect to standard inflammatory parameters and histopathology in the adjuvant arthritic rat. Arthritis Rheum. 1999;42:2060-73. (Pubitemid 30263589)
23. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, Hirano S, Yamazaki K, Yamori T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst. 2006;98:545-56. (Pubitemid 43898818)
24. Kong D, Yamori T. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3-kinase isoforms. Cancer Sci. 2007;98:1638-42. (Pubitemid 47308463)
25. Kong D, Yamori T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci. 2008;99: 1734-40.
26. Kong D, Yaguchi S, Yamori T. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol Pharm Bull. 2009;32:297-300.
27. Kong DX, Yamori T. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin. 2010;31:1189-97.
28. Toyama S, Tamura N, Haruta K, Karakida T, Mori S, Watanabe T, Yamori T, Takasaki Y. Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collageninduced arthritis in mice. Arthritis Res Ther. 2010;12:R92.
29. Sugama T. Ishihara N, Tanaka Y, Takahashi M, Yaguchi S, Watanabe T. Amorphous substance of heterocyclic compounds, solid dispersion and pharmaceutical agent containing same, and method of producing same. WO2009066775. 2009.
30. Van de Langerijt AG, Volsen SG, Hicks CA, Craig PJ, Billingham ME, Van den Berg WB. Cell migration studies in the adoptive transfer of adjuvant arthritis in the Lewis rat. Immunology. 1994;81:414-9. (Pubitemid 24245489)
31. Bush KA, Walker JS, Lee CS, Kirkham BW. Cytokine expression and synovial pathology in the initiation and spontaneous resolution phases of adjuvant arthritis: interleukin-17 expression is upregulated in early disease. Clin Exp Immunol. 2001;123: 487-95. (Pubitemid 32289970)
32. Wesch D, Marx S, Kabelitz D. Monocyte-dependent death of freshly isolated T lymphocytes: induction by phorbolester and mitogens and differential effects of catalase. J Immunol. 1998;161:1248-56. (Pubitemid 28380551)
33. Wiesenberg I, Van Der Meide PH, Schellekens H, Alkan SS. Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody. Clin Exp lmmunol. 1989;78:245-9. (Pubitemid 20009851)
34. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002;46:802-5. (Pubitemid 34214263)
35. Bober LA, Rojas-Triana A, Jackson JV, Leach MW, Manfra D, Narula SK, Grace MJ. Regulatory effects of interleukin-4 and interleukin-10 in human neutrophil function ex vivo and on neutrophil influx in a rat model of arthritis. Arthritis Rheum. 2000;43:2660-7. (Pubitemid 32001731)
36. Carter AB, Monick MM, Hunninghake GW. Both Erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol. 1999;20:751-8. (Pubitemid 129495663)
37. Kay JE, Benzie CR, Goodier MR, Wick CJ, Doe SEA. Inhibition of T-lymphocyte activation by the immunosuppressive drug FK506. Immunology. 1989;67:473-7. (Pubitemid 19203683)
38. Yaguchi S, Izumisawa Y, Sato M, Nakagane T, Koshimizu I, Sakita K, Kato M, Yoshioka K, Sakato M, Kawashima S. In vitro cytotoxicity of imidazolyl-1,3,5-triazine derivatives. Biol Pharm Bull. 1997;20:698-700. (Pubitemid 27300350)
39. Matsuno T, Karo M, Sasahara H, Watanabe T, Inaba M, Takahashi M, Yaguchi S, Yoshioka K, Sakato M, Kawashima S. Synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and benzimidazolylpyrimidine derivatives. Chem Pharm Bull (Tokyo).2000;48:1778-81.
40. Claveau D, Sirinyan M, Guay J, Gordon R, Chan CC, Bureau Y, Riendeau D, Mancini JA. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J Immunol. 2003;170:4738-44. (Pubitemid 36519982)
41. Portanova JP, Zhang Y, Anderson GD, Hauser SD, Masferrer JL, Seibert K, Gregory SA, Isakson PC. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med. 1996;184: 883-91.
42. Szekanecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM. Kenneth Haines G III, Kunkel SL, Burdick MD, Koch AE. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum. 2000;43: 1266-77. (Pubitemid 30416311)
43. Jou S-T, Carpino N, Takahashi Y, Piekorz R, Chao J-R, Carpino N, Wang D, Ihle JN. Essential, nonredundant role for the phosphoinositide 3-kinase p110d in signaling by the B-cell receptor complex. Mol Cell Biol. 2002;22:8580-91. (Pubitemid 35397173)
44. Yanaba K, Hamaguchi Y, Venturi GM, Douglas A, Steeber DA, St. Clair EW, Thomas F, Tedder TF. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol. 2007;179:1369-80.
45. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther. 2003;5(Suppl 4):S1-6. (Pubitemid 38239909)
46. Keystone EC. B cells in rheumatoid arthritis: from hypothesis to the clinic. Rheumatology. 2005;44:ii8-12.